Bokf, Na Alnylam Pharmaceuticals, Inc. Transaction History

Bokf, Na

$5.65 Billion
Q3 2024

A detailed history of Bokf, Na transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Bokf, Na holds 55 shares of ALNY stock, worth $13,934. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 5,751 99.04%

Holding current value

$13,934

Previous $1.4 Million 98.93%

% of portfolio

0.0%

Previous 0.03%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$233.81 - $287.01 $1.33 Million - $1.63 Million	-5,696 Reduced 99.04%	55 $15,000
Q2 2024 Aug 07, 2024	SELL	$143.31 - $247.0 $137,720 - $237,367	-961 Reduced 14.32%	5,751 $1.4 Million
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $189,730 - $256,668	1,295 Added 23.91%	6,712 $1 Million
Q4 2023 Feb 14, 2024	SELL	$151.41 - $196.57 $197,590 - $256,523	-1,305 Reduced 19.41%	5,417 $1.04 Million
Q3 2023 Nov 14, 2023	BUY	$170.77 - $211.65 $291,333 - $361,074	1,706 Added 34.01%	6,722 $1.19 Million
Q2 2023 Aug 21, 2023	SELL	$185.01 - $212.05 $27,566 - $31,595	-149 Reduced 2.88%	5,016 $952,000
Q1 2023 May 11, 2023	SELL	$182.66 - $235.53 $89,868 - $115,880	-492 Reduced 8.7%	5,165 $1.03 Million
Q4 2022 Feb 13, 2023	SELL	$185.53 - $241.31 $435,995 - $567,078	-2,350 Reduced 29.35%	5,657 $1.34 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $121,222 - $203,000	-875 Reduced 9.85%	8,007 $1.6 Million
Q2 2022 Aug 11, 2022	BUY	$120.42 - $169.29 $1.07 Million - $1.5 Million	8,882 New	8,882 $1.3 Million
Q3 2020 Oct 30, 2020	SELL	$121.19 - $165.49 $738,531 - $1.01 Million	-6,094 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$104.21 - $156.44 $635,055 - $953,345	6,094 New	6,094 $903,000

Others Institutions Holding ALNY

# of Institutions

644

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bokf, Na, based on Form 13F filings with the SEC.

News

Stay updated on Bokf, Na with notifications on news.

Account